ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

October 20, 2025

Conditions
Hypotension After Cardiac Surgery
Interventions
DRUG

Angiotensin II

Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.

All Listed Sponsors
lead

University of Maryland St. Joseph Medical Center

OTHER

NCT06487585 - ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery) | Biotech Hunter | Biotech Hunter